Improved i.p. drug delivery with bioadhesive nanoparticles.
The i.p. administration of chemotherapy in ovarian and uterine serous carcinoma patients by biodegradable nanoparticles may represent a highly effective way to suppress peritoneal carcinomatosis. However, the efficacy of nanoparticles loaded with chemotherapeutic agents is currently hampered by their fast clearance by lymphatic drainage. Here, we show that a unique formulation of bioadhesive nanoparticles (BNPs) can interact with mesothelial cells in the abdominal cavity and significantly extend the retention of the nanoparticles in the peritoneal space. BNPs loaded with a potent chemotherapeutic agent [epothilone B (EB)] showed significantly lower systemic toxicity and higher therapeutic efficacy against i.p. chemotherapy-resistant uterine serous carcinoma-derived xenografts compared with free EB and non-BNPs loaded with EB.
Department of Biomedical Engineering, Yale University, New Haven, CT 06511.
Yang
Y
Deng
Department of Biomedical Engineering, Yale University, New Haven, CT 06511.
Fan
F
Yang
Department of Obstetrics, Gynecology & Reproductive Sciences, School of Medicine, Yale University, New Haven, CT 06511.
Emiliano
E
Cocco
Department of Biomedical Engineering, Yale University, New Haven, CT 06511.
Eric
E
Song
Department of Biomedical Engineering, Yale University, New Haven, CT 06511; Department of Chemical & Environmental Engineering, Yale University, New Haven, CT 06511.
Junwei
J
Zhang
Department of Biomedical Engineering, Yale University, New Haven, CT 06511.
Jiajia
J
Cui
Department of Biomedical Engineering, Yale University, New Haven, CT 06511.
Muneeb
M
Mohideen
Department of Obstetrics, Gynecology & Reproductive Sciences, School of Medicine, Yale University, New Haven, CT 06511.
Stefania
S
Bellone
Department of Obstetrics, Gynecology & Reproductive Sciences, School of Medicine, Yale University, New Haven, CT 06511.
Alessandro D
AD
Santin
Department of Biomedical Engineering, Yale University, New Haven, CT 06511; Department of Chemical & Environmental Engineering, Yale University, New Haven, CT 06511 mark.saltzman@yale.edu.
W Mark
WM
Saltzman
D000269:Adhesives / Q000008:administration & dosage*; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000473:pathology; D016503:Drug Delivery Systems; D034261:Epothilones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006367:HeLa Cells; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D007274:Injections, Intraperitoneal; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry / Q000648:ultrastructure; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000473:pathology
D000269:Adhesives; D034261:Epothilones; C093788:epothilone B
chemotherapy; drug delivery; intraperitoneal; nanoparticles; ovarian cancer
BMC Cancer. 2010 Aug 02;10:402
20678220
Surg Today. 2014 May;44(5):919-26
23887848
Gynecol Oncol. 2006 Nov;103(2):391-6
16626792
Pharm Res. 2010 May;27(5):735-8
20198409
Gynecol Oncol. 2010 Oct;119(1):140-5
20673976
Womens Health (Lond). 2014 Jan;10(1):45-57
24328598
Sci Rep. 2015 Sep 01;5:13553
26324090
J Clin Oncol. 2012 Nov 1;30(31):3841-7
22987083
Nat Commun. 2015 Apr 27;6:6952
25914116
J Control Release. 2016 Oct 28;240:302-311
26776051
Chem Biol Interact. 2013 Feb 25;202(1-3):2-10
23159885
Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11751-6
23818631
Med Res Rev. 2012 Nov;32(6):1220-62
21374643
Cancer Res. 2008 Dec 15;68(24):10197-204
19074887
Mol Cancer Ther. 2015 Nov;14 (11):2519-26
26333383
Ann Surg Oncol. 2008 May;15(5):1277-9
18324445
Blood. 2005 Jan 1;105(1):350-7
15367426
ACS Biomater Sci Eng. 2015 Feb 9;1(2):64-78
25984571
Expert Rev Anticancer Ther. 2012 Jan;12(1):41-9
22149431
Drug Deliv Transl Res. 2014 Apr 1;4(2):203-9
24816829
Oncology. 2001;60(1):19-23
11150903
Small. 2010 Dec 6;6(23):2678-82
21069757
J Pharmacol Exp Ther. 2008 Dec;327(3):673-82
18780831
Biomaterials. 2014 Nov;35(34):9343-54
25112935
Pharm Res. 2007 Sep;24(9):1691-701
17447121
Clin Cancer Res. 2007 Jul 15;13(14):4178-84
17634546
Neuro Oncol. 2014 Apr;16(4):579-83
24470546
Nat Mater. 2015 Dec;14(12):1278-85
26413985
J Control Release. 2012 Mar 28;158(3):386-92
22178261
Int J Cancer. 2015 Dec 1;137(11):2618-29
26060989
J Clin Oncol. 2015 May 1;33(13):1460-6
25800756
Biomaterials. 2014 Aug;35(24):6595-602
24816286
Crit Rev Toxicol. 2005 Aug;35(7):609-62
16417045
Cancer. 2013 Jul 15;119(14):2582-92
23585021
Am J Obstet Gynecol. 2010 Aug;203(2):162.e1-8
20417484
J Drug Target. 2015;23(7-8):736-49
26453169
Nat Rev Drug Discov. 2015 Apr;14(4):239-47
25598505
Gynecol Oncol. 2014 Nov;135(2):312-7
25172762
J Biomed Mater Res A. 2006 May;77(2):351-61
16425240
J Clin Oncol. 2005 Dec 20;23(36):9048-50
16301592
Am J Obstet Gynecol. 2013 Jul;209(1):62.e1-9
23583215
J Clin Oncol. 2004 May 15;22(10):2015-25
15143095